MedTrace Logo

ANAVEX2-73 Study in Parkinson's Disease Dementia

NCT03774459 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2020-10-22

No results posted yet for this study

Summary

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD)

Conditions

  • Parkinsons Disease With Dementia

Interventions

DRUG

High dose ANAVEX2-73

Active oral capsule

DRUG

Mid dose ANAVEX2-73

Active oral capsule

DRUG

Placebo oral capsule

Placebo oral capsule

Sponsors & Collaborators

  • Anavex Germany GmbH

    collaborator INDUSTRY

  • Anavex Life Sciences Corp.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-09
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • Australia
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03774459 on ClinicalTrials.gov